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e-mail address: algarui@yahoo.com (A. Gálvez-Ruiz).Katia Sotelo Monge a; Alberto Gálvez-Ruiz d,e,⇑; Alberto Alvárez-Carrón b; César Quijada c; Anna Matheu aAbstractThe drug dasatinib is a new therapeutic option for patients with chronic myeloid leukemia (CML) as well as acute lymphocytic lym-
phoblastic leukemia (ALL). However, the scientific literature has not reached a consensus regarding the types of secondary oph-
thalmologic effects that this drug may have. In this study, we present the case of a 36-year-old male patient who was treated with
dasatinib. Two and a half months later, this patient began to experience progressive visual loss in the superior visual field of both
eyes.
After ruling out various diagnostic options and performing extensive complementary tests, the suspected diagnosis was compat-
ible with optic neuropathy secondary to dasatinib. The patient partially improved after stopping this medication and receiving oral
corticosteroid treatment.
Although secondary ophthalmological effects related to dasatinib are practically non-existent, our case is the first to report optic
neuropathy secondary to this drug.
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The etiology of chronic myeloid leukemia (CML) remains
unknown. However, recent studies have shown that this con-
dition is closely related to activation of a tyrosine kinase that
is produced as a result of rearrangement of the break point
cluster region (BCR) and Abelson murine leukemia (ABL)
genes, which are located on chromosomes 22 and 9, respec-
tively. This type of rearrangement creates the Philadelphia
translocation in CML.1
Tyrosine kinase inhibitors (TKI) are the treatment of choice
for CML. Imatinib was the first drug approved for thetreatment of CML, and it was originally used as the treatment
of choice, with an estimated 5-year survival rate of 89%.1
However, it has been recently demonstrated that dasati-
nib is more effective than imatinib as treatment for the
chronic phase of CML.5 Therefore, dasatinib, a second gener-
ation TKI used as treatment for patients intolerant or non-
responsive to imatinib, has become a first-line treatment in
patients with a recent diagnosis of CML. This superiority over
imatinib has also been demonstrated for another second-
generation TKI named nilotinib.2,3,22,23
Dasatinib has the ability to join the inactive form (similar to
imatinib) as well as the active form of the BCR/ABL tyrosinee:
al.com
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tion of the tyrosine kinase in comparison to imatinib,4,5 and
this also explains why dasatinib is effective against certain
types of CML that are resistant to imatinib.6,7 Without a
doubt, dasatinib represents a new treatment option for
patients with secondary effects or an ineffective response
to imatinib.2–4
Phase I and Phase II clinical studies have demonstrated
that the use of dasatinib is safe in patients with CML.8–11
The most frequent secondary effects in patients treated with
dasatinib are the following: headache (34%), diarrhea (30%),
fatigue (28%), skin rash (22%), nausea (19%), pleural effusion
(19%), and peripheral edema (18%). In addition, reversible
myelosuppression is one of the most important and severe
side effects associated with this drug.12–14
However, the ophthalmological secondary effects of
dasatinib, according to studies published to date, are practi-
cally non-existent or trivial. Periorbital edema secondary to
fluid retention has been reported, although to a lesser
degree than that produced by imatinib.15–17
Herein, we present the case of a patient with optic neu-
ropathy possibly related to dasatinib exposure. To the best
of our knowledge, this is the first case of optic neuropathy
secondary to dasatinib to be published.
Case report
Here, we present the case of a 36-year-old male patient,
who worked as a bus driver and was involved in a traffic acci-
dent in September 2008. As a consequence, he suffered a
spleen laceration that did not require surgical treatment. In
this accident, the patient did not suffer head trauma or loss
of consciousness. However, incidentally, the patient was
diagnosed with CML due to hematological alterations
observed in the requested complementary tests obtained
during his stay in the emergency room.
After obtaining informed consent, he was included in a clin-
ical trial for patients with CML to compare dasatinib versus
imatinib as a first-line treatment. The patient was randomly
assigned to the group that received 100 mg daily of dasatinib,
and he obtained a complete hematological response after
4 weeks of treatment and a complete cytogenetic response
after 3 months of treatment. These data were compatible with
a totally satisfactory and optimal response to treatment.
However, 2.5 months after initiating treatment, the patient
began to notice a loss in his visual field, which was subjec-
tively perceived by the patient as a scotoma located in the
superior region of both eyes.
For this reason, the patient was referred for neuro-oph-
thalmology consultation to evaluate this visual field defect.
In the neuro-ophthalmological examination, the patient dem-
onstrated a visual acuity of 20/100 in the right eye (RE) and
20/20 in the left eye (LE). The presence of a relative afferent
pupillary defect in the RE was observed. Through the Ishihara
test, color vision was noted to be altered in the RE, where the
patient was unable to identify any of the plates; the LE was
normal.
The patient’s visual field, as assessed through campimetry
by confrontation, presented a supero-temporal defect in the
RE and a normal left eye. Through Humphrey visual field test-
ing (HVF) 24-2, the existence of a superior arcuate defect was
observed in the RE [mean deviation (MD) of 15.47 dB], anda superior arcuate defect was observed in the LE (MD of
5.39 dB) (Fig. 1).
Slit lamp examination did not show any abnormalities,
although fundus examination showed slight temporal pallor
in the optic nerve in the RE and a normal optic nerve in the
LE (Fig. 2).
The study was completed by performing a global electro-
retinogram (ERG), which demonstrated normal results, and
obtained visually evoked potentials (VEP), which showed axo-
nal loss in both optic nerves (more marked in the RE) (Fig. 3).
Extensive laboratory tests were obtained, including serol-
ogy for common infectious diseases (syphilis, HIV, Herpes
virus, cytomegalovirus, Epstein Barr virus, Adenovirus, Bru-
cella, Hepatitis A-B-C, and Bartonella), immunologic diseases
(ANA, Anti-DNA, Anti-Ro, Anti-La, c-ANCA, and rheumatoid
factor), and vitamins (B6, B1, B12, and folic acid). All of these
results were within the normal limits. A lumbar puncture with
an opening pressure of 19 cm of H2O was also conducted,
and all biochemical, microbiological, and cytological analyses
were within the normal limits.
Head and orbital magnetic resonance imaging (MRI) was
also normal.
After conducting all complementary evaluations, it was
suspected that dasatinib could be the cause of the optical
neuropathy, and treatment with this drug was suspended.
Treatment with oral prednisone, at 100 mg daily, was initi-
ated for 3 weeks, followed by a progressive decrease in the
dose until its suspension 1 month after initiation.
Two months later, the ophthalmologic examination was
repeated, at which time the patient demonstrated a VA of
20/50 in the RE and 20/20 in the LE. The HVF was repeated,
and it showed improvement with a decrease in the size and
density of the visual field defects in both eyes. We cannot rule
out completely that this improvement can be explained by a
learning effect doing the visual field. Fig. 4 shows the pres-
ence of a superior arcuate defect in the RE (MD 13.2 dB)
and a residual paracentral scotoma in the LE (MD
1.94 dB). Six months later, the patient’s VA improved to
20/30 in the RE and 20/20 in the LE. However, the defects
in the visual field remained without significant changes; these
included the presence of a superior arcuate defect in the RE
(MD 11.94 dB) and a residual paracentral scotoma in the LE
(MD 1.44 dB).
Lastly, the VEPs were repeated 1 year later, showing a
slight improvement of the P100 wave in the RE, but with con-
tinued asymmetry of the amplitude in the LE.
After improvement of visual function and considering the
good hematological response to initial treatment with dasat-
inib, the Hematology service proposed to initiate treatment
with nilotinib, a drug that differs from dasatinib but is within
the same family. After patient agreement, this treatment was
initiated with good tolerance. However, after 2 months of
treatment, the patient began to note photopsia in the area
of the residual scotoma of the RE, which spontaneously went
into remission after several days. After repeat neuro-ophthal-
mological evaluation, it was confirmed that the VA, as well as
the HVF, remained without changes in both eyes compared
to the patient’s situation prior to the initiation of treatment
with nilotinib. Taking into account that these visual symptoms
were very transient, it was decided to continue treatment
with nilotinib, and to this date, the patient remains
asymptomatic.
Figure 1. HVF testing 24-2. LE (represented to the left): Presence of a superior arcuate defect (MD 5.39 dB). RE (represented to the right): Presence of
a superior arcuate defect (MD 15.47 dB).
Figure 2. Fundus examination of the eye showing mild pallor in the temporal area of the RE and a normal appearance in the LE.
Optic neuropathy secondary to dasatinib 229Discussion
TKIs are the treatment of choice for patients with
CML. 10,14,22,23 Trivial ophthalmological secondary (side)
effects like periorbital edema have been described in
patients who received treatment with imatinib.18,19
In the reviewed scientific literature, we found a case of a
patient who, 26 days after initiating treatment with imatinib,
suffered from progressive bilateral visual loss. This report
suggests the role of imatinib as a cause of optic
neuropathy.20In another study, Breccia et al. studied ophthalmological
secondary effects in 250 CML patients treated with imatinib.
Of these 250 patients, only a single patient developed optic
neuritis. This patient demonstrated a complete recovery of
visual function upon stopping the treatment and receiving
vitamin supplements (B complex) and oral corticosteroids.
Imatinib was re-initiated 14 days later without any reoccur-
rence of toxicity.19
Our patient, after receiving dasatinib, presented with an
optic neuropathy that was manifested clinically as VA loss in
the RE and bilateral visual field involvement. After suspension
Figure 3. Consistent simultaneous monocular visual stimulus in a 30–60 inverse pattern applied to obtain macular and pattern-evoked potentials. The
result was compatible with axonal loss in the optic nerve. There was discrete asymmetry in the amplitude of the cortical responses (P 100), where the
wave in the RE was slightly smaller. The responses of both eyes showed waves below the normal range. The latencies were bilateral without asymmetry
between both eyes.
Figure 4. HVF testing 24.2 (obtained 2 months after the first examination). LE (represented to the left): Presence of a residual paracentral scotoma (MD
1.44 dB). RE (represented to the right): There is improvement in the density of the superior arcuate defect (MD 11.94 dB).
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clear improvement in VA (with recovery back to normal).
Given that our patient was a bus driver, he was very
concerned with his visual function in order to maintain his
profession. For this reason, he opposed the re-introduction
of dasatinib. However, this patient did agree to initiatingtherapy with nilotinib (a second-line TKI that belongs to the
same family as dasatinib).
After beginning treatment with nilotinib, the patient
experienced mild photopsia in the area of the previous
residual scotomas. Given that the symptoms were very
mild and his VA and visual campimetry were not affected,
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eral days, these symptoms went into remission, and the
patient remained asymptomatic after several months of
treatment.
Although this relapse in visual symptoms was much more
mild and occurred following exposure to a drug within the
same family, we can assume that these symptoms were iden-
tical secondary effects to those observed with dasatinib.
The World Health Organization (WHO) has established a
series of criteria to obtain evidence of the cause-effect rela-
tionship between a certain pharmaceutical principal and a
secondary effect. These criteria include temporal association,
relationship with the dosage, improvement after discontinua-
tion, worsening after re-introduction, possible pathophysio-
logical mechanism, similar effects after introduction of
drugs in the same family, and absence of alternative mecha-
nisms that may explain the secondary effect.21
Applying these criteria to our patient, we identified the
following: a temporal association; a relationship with the dos-
age (progressive worsening with dosage increase); improve-
ment after removal of the drug and worsening after re-
introduction of nilotinib (drug within the same family); and
the lack of an alternative pathophysiologic mechanisms that
could explain the optic neuropathy (after extensive diagnos-
tic tests). Taking into account the WHO classification, we
therefore define the relationship of causality between dasat-
inib and optic neuropathy in our patient as probable.
In summary, to the best of our knowledge, this is the first
case of toxic optic neuropathy related to exposure to dasat-
inib. Despite suspending this medication, the visual field
defects in our patient persisted, which suggests an irrevers-
ibility of this toxicity. However, the mechanisms by which TKIs
produce optic neuropathy remain unclear. Moreover,
although we cannot be sure that there is similar toxicity for
other TKIs, the fact that reintroduction of nilotinib in our
patient led to a mild and transient reoccurrence of symptoms
indicates that this secondary effect could also occur for TKIs
of the same family.
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